LON:SUMMSummit Therapeutics Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 20.50 0.00 (0.00 %) (As of 02/21/2020) Add Compare Share Today's Range 18Now: GBX 20.50▼ 20.5050-Day Range 20.50MA: GBX 20.50▼ 20.5052-Week Range 18Now: GBX 20.50▼ 30Volume268,382 shsAverage Volume34,608 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Summit Therapeutics. Previous Next 2.1 Community Rank Outperform VotesSummit Therapeutics has received 165 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSummit Therapeutics has received 237 “underperform” votes. (Add your “underperform” vote.)Community SentimentSummit Therapeutics has received 58.96% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics and other stocks. Vote “Outperform” if you believe SUMM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SUMM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Summit Therapeutics are expected to grow in the coming year, from GBX (33.40) to GBX 0 per share. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.55 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drugs - Generic Sub-IndustryN/A SectorMedical Current SymbolLON:SUMM Previous Symbol CUSIPN/A CIKN/A Webwww.summitplc.com Phone+44-1235-443939Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable LSE:SUMM Rates by TradingView Receive SUMM News and Ratings via Email Sign-up to receive the latest news and ratings for SUMM and its competitors with MarketBeat's FREE daily newsletter. Summit Therapeutics (LON:SUMM) Frequently Asked Questions How has Summit Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Summit Therapeutics' stock was trading at GBX 20.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SUMM stock has increased by 0.0% and is now trading at GBX 20.50. View which stocks have been most impacted by Coronavirus. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics PLC (LON:SUMM) announced its quarterly earnings results on Wednesday, June, 12th. The company reported ($3.00) EPS for the quarter, topping analysts' consensus estimates of ($4.00) by $1.00. View Summit Therapeutics' earnings history. Has Summit Therapeutics been receiving favorable news coverage? News articles about SUMM stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Summit Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutSummit Therapeutics. Who are some of Summit Therapeutics' key competitors? Some companies that are related to Summit Therapeutics include 1933 Industries (TGIF), 21st North (ULGX), 89bio (ETNB), AAC Technologies (ABSCF), Abacus Health Products (ABAHF), Abattis Bioceuticals (ATT), Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Acreage (ACRGF), Admedus (AHZ), Advanz Pharma (CXRXF), AEGON (AGN), Aeolus Pharmaceuticals (AOLS) and Affymax (AFFY). View all competitors. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include SUMMIT THERAPEU/S (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Avesoro Resources (ASO), Diana Shipping (DSX), Jelf Group (JLF), National Fuel Gas (NFG), Tailored Brands (TLRD), Weir Group (WEIR) and Acacia Mining (ABGLF). Who are Summit Therapeutics' key executives? Summit Therapeutics' management team includes the following people: Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)Mr. Erik Ostrowski, Chief Financial Officer (Age 46)Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)Ms. Michelle Avery, Director of Investor Relations What is Summit Therapeutics' stock symbol? Summit Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SUMM." How do I buy shares of Summit Therapeutics? Shares of SUMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Summit Therapeutics' stock price today? One share of SUMM stock can currently be purchased for approximately GBX 20.50. What is Summit Therapeutics' official website? The official website for Summit Therapeutics is www.summitplc.com. How can I contact Summit Therapeutics? Summit Therapeutics' mailing address is 136A Eastern Avenue, ABINGDON, OX14 4SB, United Kingdom. The company can be reached via phone at +44-1235-443939. This page was last updated on 5/25/2020 by MarketBeat.com Staff
